你可能會喜歡
The team at ImmunityBio extends our congratulations to Dr. Mary E. Brunkow, Dr. Fred Ramsdell, and Dr. Shimon Sakaguchi, recipients of the 2025 Nobel Prize in Physiology or Medicine. This groundbreaking research on regulatory T cells has advanced the scientific understanding of…
ImmunityBio is continuously pursuing new immunotherapies designed to attack disease by enhancing the patient’s immune system, not weakening it. View our pipeline: immunitybio.com/pipeline/
Lung cancer remains one of the leading causes of cancer-related deaths worldwide. At ImmunityBio, we are advancing clinical research to explore new treatment options that harness the immune system. Our goal is to help expand possibilities for patients facing this disease. Learn…
With high rates of recurrence and the risk of advancing disease, non-muscle invasive bladder cancer (NMIBC) remains a significant burden for both patients and healthcare providers. ImmunityBio is working to meet this challenge through the development of innovative treatment…
Recombinant BCG addressing #BladderCancer treatment shortages. @DrPatSoonShiong @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss efforts to address BCG shortage with "supercharged" recombinant BCG, showing unprecedented efficacy & less toxicity. The FDA expanded access…
Protecting immune cells before radiation in #ProstateCancer treatment. @DrPatSoonShiong @ImmunityBio and @UroDocAsh @MDAndersonNews discuss N-803 immunotherapy & its potential to protect immune cells before radiation. #WatchNow for insights into innovative cancer care >…
We’ve announced new paradigm-changing findings from the Phase 2 QUILT-3.055 study, demonstrating ANKTIVA® (nogapendekin alfa inbakicept-pmln) reverses lymphopenia (low natural killer and T cells) in patients with checkpoint inhibitor-resistant advanced non-small cell lung cancer…
September marks Ovarian Cancer Awareness Month; a time to highlight the importance of early detection and ongoing research in the fight against this disease. Our team is always striving to push the boundaries of what is possible in ovarian cancer treatment. This month, and every…
We're focused on innovating beyond standard treatments so that we can give the body the tools it needs to lead its own fight against cancer. Learn more about our pipeline: immunitybio.com/pipeline/
Initial data shows 2 patients with near Complete Response & 100% disease control in first 5 patients. When the immune system is protected, CR in tumors difficult to treat in recurrent GBM is possible. GBM trial open at CSSIFM.org Data for lung cancer next #WCLC25
We’ve announced that our initial data shows 100% disease control in 5 out of 5 patients with recurrent glioblastoma after being treated with our ANKTIVA, NK cell therapy plus the Optune Gio® device. Read more: immunitybio.com/initial-data-s…
We've announced our new study, called COVID-4.019-Long, which further expands our clinical research efforts to assess ANKTIVA’s potential beyond cancer or cancer-related diseases. Learn more about the study and its potential impact: ir.immunitybio.com/news-releases/…
Recombinant BCG addressing #BladderCancer treatment shortages. @DrPatSoonShiong @ImmunityBio joins @UroDocAsh @MDAndersonNews to discuss efforts to address BCG shortage with "supercharged" recombinant BCG, showing unprecedented efficacy & less toxicity. The FDA expanded access…
30 Years and $3B Toward a Universal Cancer Fighter - Patrick Soon-Shiong @DrPatSoonShiong @ImmunityBio @bullishbruk @Rainmaker1973 oncodaily.com/drugs/patrick-… #OncoDaily #Oncology #Cancer #Health #Medicine #MedX #MedEd #MedNews #ANKTIVA @CancerWorldmag
Protecting immune cells before radiation in #ProstateCancer treatment. @DrPatSoonShiong @ImmunityBio and @UroDocAsh @MDAndersonNews discuss N-803 immunotherapy & its potential to protect immune cells before radiation. #WatchNow for insights into innovative cancer care >…
We announced early results from our QUILT-106 Phase I trial showing complete responses in the first two late-stage Non-Hodgkin Waldenström lymphoma patients treated with our CD19 CAR-NK cell therapy. Learn more: immunitybio.com/immunitybio-re…
Reviewing Exciting Multi-Tumor Data from Patients on the Bioshield Platform - Pat Soon-Shiong @DrPatSoonShiong oncodaily.com/voices/pat-soo… #OncoDaily #Oncology #Cancer #Health #Medicine #MedTwitter #MedEd #MedOnc #MedNews
Our robust pipeline of clinical trials is all about turning insights into better outcomes for people facing a wide range of cancers. The ImmunityBio team remains committed to transforming research into tangible impact in the lives of patients. Explore our latest trials:…
Veterans are at an increased risk for bladder cancer due to exposure to carcinogens during service. Houston's Michael E. DeBakey VA Medical Center is now among the first VA hospitals to offer ANKTIVA® for eligible veterans with BCG-unresponsive NMIBC. Read more:…
United States 趨勢
- 1. Jets 79.5K posts
- 2. Jets 79.5K posts
- 3. Justin Fields 8,278 posts
- 4. Aaron Glenn 4,338 posts
- 5. #HardRockBet 3,331 posts
- 6. Sean Payton 2,027 posts
- 7. London 202K posts
- 8. Garrett Wilson 3,243 posts
- 9. Bo Nix 3,301 posts
- 10. HAPPY BIRTHDAY JIMIN 147K posts
- 11. Tyrod 1,536 posts
- 12. #OurMuseJimin 192K posts
- 13. #DENvsNYJ 2,079 posts
- 14. #JetUp 1,916 posts
- 15. Peart 1,897 posts
- 16. #30YearsofLove 168K posts
- 17. Bam Knight N/A
- 18. Kurt Warner N/A
- 19. Rich Eisen N/A
- 20. Anthony Richardson N/A
你可能會喜歡
-
Dr. Pat Soon-Shiong
@DrPatSoonShiong -
ArsenalBio
@ArsenalBio -
Guru P. Sonpavde, MD
@sonpavde -
Trades by Matt
@TradesByMatt -
ERNEST B. MAKULILO (EBM)
@EBMSCHOLARS -
Altimmune, Inc.
@AltimmuneInc -
Siemens Deutschland
@SiemensDE -
Ayana Bio
@AYANA_BIO -
Iovance Biotherapeutics
@IovanceBio -
Structure Therapeutics
@StructureTx -
MeiraGTx
@MeiraGTx -
Centessa Pharmaceuticals
@centessa -
Steve Moore💙
@SteveMo95030589 -
Cancer Drug Resistance
@cdrjournal -
Palleon Pharma
@Palleon_Pharma
Something went wrong.
Something went wrong.